| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/05/2006 | US7101699 Comprises enzymatic polypeptide for treatment and prevention of neurodegenerative and cell proliferative disorders; wound healing agents |
| 09/05/2006 | US7101695 Preparing protein cross-linking enzymes for use in food processing and drug delivevry |
| 09/05/2006 | US7101689 Interleukin-18 binding proteins, their preparation and use |
| 09/05/2006 | US7101688 Method of producing heteromultimeric mammalian proteins in plants |
| 09/05/2006 | US7101675 Modulators of regulatory proteins |
| 09/05/2006 | US7101674 Antiidiotypic antibody for treating prevention and diagnosis of sepsis, inflammation, cancer and autoimmune disorders |
| 09/05/2006 | US7101670 Computerized genotype analysis of microsatellite sequences; hepatitis C virus |
| 09/05/2006 | US7101667 Lanthanide binding tags |
| 09/05/2006 | US7101664 Using short chained amino acid sequences to increase yield of preferential cell products in animal or plant cultures; bioreactors |
| 09/05/2006 | US7101562 Conjugate vaccines for the prevention of dental caries |
| 09/05/2006 | US7101559 Immunomodulatory protein and useful embodiments thereof |
| 09/05/2006 | US7101557 Promoting coagulation in prothrombotic blood vessels, treating a vascularized tumor with a coagulation-deficient tissue factor compound |
| 09/05/2006 | US7101556 Preparation and usage of plasmodium fusion antigen |
| 09/05/2006 | US7101555 Microorganismal polypeptides for use in diagnosis and treatment of respiratory system disorders; genetic vaccines |
| 09/05/2006 | US7101554 Picornaviruses, vaccines and diagnostic kits |
| 09/05/2006 | US7101550 Agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in a immune cell resulting in modulation of the immune response |
| 09/05/2006 | US7101549 nucleic acid molecules and polypeptide molecules that encode glycoprotein VI; modulating agents in regulating a variety of cellular processes |
| 09/05/2006 | US7101548 Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology |
| 09/05/2006 | US7101546 Encapsulating a cell culture of propagating pancreatic cells; inserting the encapsulated cells into the mammal permitting the cells to mature to insulin secreting cells |
| 09/05/2006 | US7101541 Utilization of non-viral sequences for minus-strand DNA transfer and gene reconstitution |
| 09/05/2006 | US7101539 Increasing hematopoietic progenitor cells in a mammal by adminstering an interleukin-like polypeptide |
| 09/05/2006 | CA2393640C Pyrrolo[2,3-d]pyrimidine compounds |
| 09/05/2006 | CA2143642C Immunoreactive peptides from epstein-barr virus |
| 09/03/2006 | WO2006096164A1 Media for clostridium bacterium and processes for obtaining a clostridial toxin |
| 09/02/2006 | CA2513350A1 Treatment for multiple sclerosis |
| 09/02/2006 | CA2496690A1 A novel c. elegans p21-activated kinase (pak) gene and associated loss-of-function phenotypes that facilitate screening for small molecule modulators of pak activity in the nematode, caenorhabditis elegans |
| 08/31/2006 | WO2006091965A2 Nod1 as an anti-tumor agent |
| 08/31/2006 | WO2006091871A1 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| 08/31/2006 | WO2006091763A2 Ultrasonically assisted dermal or transdermal delivery substance preparation |
| 08/31/2006 | WO2006091729A2 Revascularization of ischemic retinal tissue and screening method therefor |
| 08/31/2006 | WO2006091728A2 Microtubule stabilizing compounds and methods of their use |
| 08/31/2006 | WO2006091727A2 Single branch heparin-binding growth factor analogs |
| 08/31/2006 | WO2006091637A1 Microglia facilitated amyloidogenesis assay |
| 08/31/2006 | WO2006091506A2 Neuropeptide y4 receptor agonists |
| 08/31/2006 | WO2006091459A2 Compositions and methods for treating vascular permeability |
| 08/31/2006 | WO2006091395A2 Inhibitors of akt activity |
| 08/31/2006 | WO2006091229A2 Methods of modulating intracellular degradation rates of toxins |
| 08/31/2006 | WO2006091035A1 A therapeutic agent comprising lipocalin 2 against cancer metastasis, and methods of early diagnosis and inhibition of cancer metastasis using lipocalin2 |
| 08/31/2006 | WO2006090849A1 Preventive or remedy for inflammatory ocular surface diseases |
| 08/31/2006 | WO2006090767A1 PROMOTER OF REGENERATION OF PANCREATIC β CELL, AND PROMOTER OF INSULIN PRODUCTION IN PANCREATIC β CELL |
| 08/31/2006 | WO2006090697A1 Therapeutic agent for disease with apoptotic degeneration in eye tissue cell containing pedf and fgf2 |
| 08/31/2006 | WO2006090689A1 Remedy for disease associated with apoptotic degeneration in ocular cell tissue with the use of siv-pedf vector |
| 08/31/2006 | WO2006090555A1 Akt ACTIVATING AGENT |
| 08/31/2006 | WO2006090544A1 Chewable tablet containing collagen peptide and process for producing the same |
| 08/31/2006 | WO2006090494A1 Anticancer agent |
| 08/31/2006 | WO2006090127A1 Pharmaceutical formulation |
| 08/31/2006 | WO2006089987A1 Use of leptin for the prevention of excess body weight and composition containing leptin |
| 08/31/2006 | WO2006089953A1 Compounds for stabilizing factor vii polypeptide formulations |
| 08/31/2006 | WO2006089952A1 Amidino-compounds por stabilizing factor vii polypeptide formulations |
| 08/31/2006 | WO2006089586A1 Use of a compound with clusterin activity for the treatment of diseases associated with the deposition of abnormal proteins |
| 08/31/2006 | WO2006089549A1 Ykl-40 monoclonal antibodies |
| 08/31/2006 | WO2006089455A1 Targeting anti-tumour fusion protein containing adenovirus e4orf4 protein |
| 08/31/2006 | WO2006089338A1 Extraction of gelatin |
| 08/31/2006 | WO2006076119A3 Treatment of skin diseases |
| 08/31/2006 | WO2006066595A3 Recombinant production of serum albumin |
| 08/31/2006 | WO2006064133A3 Novel multimeric cd40 ligands, method for preparing same and use thereof for preparing drugs |
| 08/31/2006 | WO2006059105A3 Non-cytotoxic protein conjugates |
| 08/31/2006 | WO2006053613A3 Skin care composition comprising fusion polypeptide composition |
| 08/31/2006 | WO2006053134A3 Deamidated interferon-beta |
| 08/31/2006 | WO2006052787A3 Liquefaction of starch-containing material |
| 08/31/2006 | WO2006048862A3 The use of a protease or a protease inhibitor for the manufacture of medicaments |
| 08/31/2006 | WO2006048452A3 Peptides for use in treating of obesity |
| 08/31/2006 | WO2006048450A3 Peptides for use in the treating obesity |
| 08/31/2006 | WO2006045066A3 Labeled compounds for proteasome inhibition |
| 08/31/2006 | WO2006044566A3 Autocrine growth factor receptors and methods |
| 08/31/2006 | WO2006040574A3 Lipocalin protein |
| 08/31/2006 | WO2006040481A3 Method for diagnosing and treating crohn's disease |
| 08/31/2006 | WO2006038206A3 Compounds that modulate trh actions and inhibit the trh-degrading enzyme |
| 08/31/2006 | WO2006038107A3 Method for inhibiting fibrogenesis by an rhdecorin-fc fusion protein |
| 08/31/2006 | WO2006035445A3 Methods of treating pathologies associated with oxidative stress |
| 08/31/2006 | WO2006032781A3 Peptide derivatives, compositions and uses in therapeutic treatment of herpesvirus infection |
| 08/31/2006 | WO2006024694A3 Peptide inhibitors of hk2 and their use |
| 08/31/2006 | WO2005107792A3 Compositions and methods for treatment of protein misfolding diseases |
| 08/31/2006 | WO2005067890A3 Controlled release cgrp delivery composition for cardiovascular and renal indications |
| 08/31/2006 | WO2005058252A3 Glp-1 pharmaceutical compositions |
| 08/31/2006 | WO2005015159A3 Methods for modulating a drug-related effect or behavior |
| 08/31/2006 | WO2004094623A3 Cell adhesion and extracellular matrix proteins |
| 08/31/2006 | WO2004033657A3 Heat shock protein binding fragments of cd91, and uses thereof |
| 08/31/2006 | WO2004033648A3 Isolated mammalian membrane protein genes; related reagents |
| 08/31/2006 | US20060195945 Method for preparing fusion polypeptide comprising epidermal growth factor and human serum albumin in plants |
| 08/31/2006 | US20060195915 mesencephalic astrocyte-derived neurotrophic factor polypeptide; shown to protect the survival of embryonic mesencephalic dopaminergic neurons in culture |
| 08/31/2006 | US20060194954 Immunoadhesin protein for use as tools in targeting preferential cells for destruction |
| 08/31/2006 | US20060194951 Polynucleotides encoding interferon gamma polypeptides |
| 08/31/2006 | US20060194947 Peptide gap junction modulators |
| 08/31/2006 | US20060194940 Water-soluble polymer alkanals |
| 08/31/2006 | US20060194881 Composition comprising at least one alkanolamide to inhibit megration of langerhans cells and uses therof |
| 08/31/2006 | US20060194755 Compositions and methods for regulating an immune response in a subject |
| 08/31/2006 | US20060194753 Agent for treating leishmania infections |
| 08/31/2006 | US20060194742 Pyrane derivatives as both ACE- and NEP-inhibitors |
| 08/31/2006 | US20060194741 Dimeric IAP inhibitors |
| 08/31/2006 | US20060194740 NOD1 as an anti-tumor agent |
| 08/31/2006 | US20060194739 Nociceptin-based analgesics |
| 08/31/2006 | US20060194738 Cytomodulating peptides for treating interstitial cystitis |
| 08/31/2006 | US20060194737 Hepta-, octa-and nonapeptides having antiangiogenic activity |
| 08/31/2006 | US20060194736 Polypeptide for the treatment of cancer and a method for preparation thereof |
| 08/31/2006 | US20060194735 Extending the shelf life of Therapeutic protein X; nucleic acids and vectors containing them; kits; treating, preventing, or ameliorating diseases, disorders or conditions |
| 08/31/2006 | US20060194734 Cardiac muscle function and manipulation |
| 08/31/2006 | US20060194733 Substantially non-immunogenic injectable collagen |
| 08/31/2006 | US20060194732 Lipid-free powder form of surfactant protein A with a carrier; microbiocides; antiinflammatory and bronchodilator agents |
| 08/31/2006 | US20060194731 Using tumor antigens to elicit immune response targeted to cancer cells; immunotherapy |